• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

    10/28/24 4:03:06 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OKUR alert in real time by email
    SC 13G/A 1 y1028240sc13ga1.htm AMENDMENT NO. 1

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    OnKure Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, $0.0001 par value
    (Title of Class of Securities)

     

      68277Q105  
      (CUSIP Number)  
     
    October 4, 2024
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x Rule 13d-1(b)
         
      ¨ Rule 13d-1(c)
         
      ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 8 
     

     

    CUSIP No.  68277Q105
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Octagon Capital Advisors LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)¨

    (b)¨

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    225,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    225,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    225,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.8%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    IA, PN

     

     Page 2 of 8 
     

     

    CUSIP No.  68277Q105
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Octagon Investments Master Fund LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)¨

    (b)¨

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    225,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    225,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    225,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.8%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    OO, PN

     

     Page 3 of 8 
     

     

    CUSIP No.  68277Q105
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ting Jia

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)¨

    (b)¨

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    China

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    225,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    225,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    225,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.8%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, IN

     

     Page 4 of 8 
     

     

    Item 1(a). Name of Issuer:
       
       OnKure Therapeutics, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      

    6707 Winchester Circle, Suite 400, Boulder, CO 80301

       
    Item 2(a). Name of Person Filing:
       
      

    This statement is being jointly filed by:

     

    Octagon Capital Advisors LP (“Octagon”)

    Octagon Investments Master Fund LP (“Master Fund”)

    Ting Jia, as the principal beneficial owner of Octagon (“Mr. Jia”)

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Octagon serves as the investment manager of the Master Fund. Mr. Jia is the managing member of Octagon. By virtue of these relationships each of Octagon and Mr. Jia may be deemed to beneficially own the Issuer’s Common Shares directly owned by the Master Fund.

     

       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
         
       The address of the business office of each of the Reporting Persons is 654 Madison Avenue, 21st Floor, New York, NY 10065
       
    Item 2(c). Citizenship:
       
       Octagon is a Delaware limited partnership. The Master Fund is an exempted limited partnership established in the Cayman Islands. Mr. Jia is a Chinese citizen.
       
    Item 2(d). Title of Class of Securities:
       
       Common Stock, $0.0001 par value (the “Common Shares”)
       
    Item 2(e). CUSIP Number:  68277Q105

     

     Page 5 of 8 
     

     

    Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:      

     

    Item 4. Ownership.
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a) Amount Beneficially Owned: 225,000
       (b)

    Percent of Class:

    1.8%
          The percentage reported on this Schedule 13G is calculated based upon a statement in the Issuer’s Current Report on Form 8-K filed on October 8, 2024 that there would be 12,652,811 Class A Common Shares outstanding immediately after the closing of the Issuer’s merger with Reneo Pharmaceuticals, Inc. and concurrent private placement.  
       (c)

    Number of shares as to which such person has:

          (i) sole power to vote or to direct the vote: 0
          (ii) shared power to vote or to direct the vote: 225,000
          (iii) sole power to dispose or to direct the disposition of: 0
          (iv) shared power to dispose or to direct the disposition of: 225,000

     

     Page 6 of 8 
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
       
     Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
       Octagon is the investment advisor to the Master Fund and other accounts. Mr. Jia is the control person of Octagon. The Master Fund holds the Common Shares for the benefit of its investors. The Master Fund and Octagon, for the benefit of its investors, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
       Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
       Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
       Not applicable.
       
    Item 10. Certification.
       
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     Page 7 of 8 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 28, 2024 OCTAGON CAPITAL ADVISORS LP
       
      /s/ Ting Jia  
      Name: Ting Jia  
      Title: Managing Member  

     

     

     

      OCTAGON INVESTMENTS MASTER FUND LP
      By: Octagon Investments GP, LLC, its general partner

     

      /s/ Ting Jia  
      Name: Ting Jia  
      Title: Managing Member  
     

     

     

     

    TING JIA

     

    /s/ Ting Jia

     
      Name: Ting Jia  

     

     

    Page 8 of 8

     

     

     

    Get the next $OKUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OKUR

    DatePrice TargetRatingAnalyst
    4/30/2025Outperform
    Evercore ISI
    12/5/2024$33.00Outperform
    Leerink Partners
    10/10/2024$35.00Outperform
    Oppenheimer
    More analyst ratings

    $OKUR
    Leadership Updates

    Live Leadership Updates

    See more
    • OnKure Announces New Date for Upcoming Investor Call

      BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10th. OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. E

      11/25/24 5:31:00 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OKUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

      -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's PI3Ka franchise with the planned announcement of a pan-mutant selective development candidate in Q2 2025 -- $96.7M in cash and cash equivalents expected to be sufficient to fund operations through multiple anticipated milestones into Q4 2026 BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today reported financial results for the quarter ended Mar

      5/6/25 7:30:00 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      — PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 — Expansion of PI3Ka franchise to include a pan-mutant selective program; development candidate expected to be announced in Q2 2025 — $111M in cash and cash equivalents expected to be sufficient to fund operations through multiple PIKture-01 clinical readouts and anticipated milestones into Q4 2026 BOULDER, Colo., March 10, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, to

      3/10/25 4:05:16 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

      BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Leerink Partners Global Healthcare Conference, in Miami on Tuesday, March 11, 2025, at 4:20 p.m. ET. A live audio webcast will be available through this link and the Investors section of OnKure's website at www.onkure.com. Following the event, a replay will be availa

      3/4/25 8:00:00 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OKUR
    Financials

    Live finance-specific insights

    See more
    • OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

      -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025 -- Management to host conference call today, December 10, 2024 at 7:00 a.m. CT BOULDER, Colo., Dec. 10, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medi

      12/10/24 7:00:00 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

      OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D

      11/1/24 5:30:00 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OKUR
    SEC Filings

    See more
    • SEC Form 424B3 filed by OnKure Therapeutics Inc.

      424B3 - OnKure Therapeutics, Inc. (0001637715) (Filer)

      5/6/25 7:45:20 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by OnKure Therapeutics Inc.

      10-Q - OnKure Therapeutics, Inc. (0001637715) (Filer)

      5/6/25 7:40:20 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OnKure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)

      5/6/25 7:35:09 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OKUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $OKUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OKUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

      SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

      11/14/24 4:00:05 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by OnKure Therapeutics Inc.

      SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

      11/14/24 10:11:45 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

      SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

      10/28/24 4:03:06 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Cormorant Asset Management, Lp sold $48,236 worth of shares (24,300 units at $1.99) (SEC Form 4)

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      5/14/25 4:36:04 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Saccomano Nicholas A sold $2,570 worth of shares (874 units at $2.94), decreasing direct ownership by 19% to 3,682 units (SEC Form 4)

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      4/8/25 5:32:14 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Leverone Jason A. sold $9,178 worth of shares (3,122 units at $2.94), decreasing direct ownership by 19% to 13,209 units (SEC Form 4)

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      4/8/25 5:30:50 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on OnKure Therapeutics

      Evercore ISI initiated coverage of OnKure Therapeutics with a rating of Outperform

      4/30/25 8:12:14 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on OnKure Therapeutics with a new price target

      Leerink Partners initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $33.00

      12/5/24 8:06:23 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on OnKure Therapeutics with a new price target

      Oppenheimer initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $35.00

      10/10/24 7:48:05 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care